• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of frontmicrobioLink to Publisher's site
Front Microbiol. 2012; 3: 130.
Published online Apr 23, 2012. doi:  10.3389/fmicb.2012.00130
PMCID: PMC3332394

Secondary Metabolites from Plants Inhibiting ABC Transporters and Reversing Resistance of Cancer Cells and Microbes to Cytotoxic and Antimicrobial Agents

Abstract

Fungal, bacterial, and cancer cells can develop resistance against antifungal, antibacterial, or anticancer agents. Mechanisms of resistance are complex and often multifactorial. Mechanisms include: (1) Activation of ATP-binding cassette (ABC) transporters, such as P-gp, which pump out lipophilic compounds that have entered a cell, (2) Activation of cytochrome p450 oxidases which can oxidize lipophilic agents to make them more hydrophilic and accessible for conjugation reaction with glucuronic acid, sulfate, or amino acids, and (3) Activation of glutathione transferase, which can conjugate xenobiotics. This review summarizes the evidence that secondary metabolites (SM) of plants, such as alkaloids, phenolics, and terpenoids can interfere with ABC transporters in cancer cells, parasites, bacteria, and fungi. Among the active natural products several lipophilic terpenoids [monoterpenes, diterpenes, triterpenes (including saponins), steroids (including cardiac glycosides), and tetraterpenes] but also some alkaloids (isoquinoline, protoberberine, quinoline, indole, monoterpene indole, and steroidal alkaloids) function probably as competitive inhibitors of P-gp, multiple resistance-associated protein 1, and Breast cancer resistance protein in cancer cells, or efflux pumps in bacteria (NorA) and fungi. More polar phenolics (phenolic acids, flavonoids, catechins, chalcones, xanthones, stilbenes, anthocyanins, tannins, anthraquinones, and naphthoquinones) directly inhibit proteins forming several hydrogen and ionic bonds and thus disturbing the 3D structure of the transporters. The natural products may be interesting in medicine or agriculture as they can enhance the activity of active chemotherapeutics or pesticides or even reverse multidrug resistance, at least partially, of adapted and resistant cells. If these SM are applied in combination with a cytotoxic or antimicrobial agent, they may reverse resistance in a synergistic fashion.

Keywords: ABC transporter, P-gp, MDR, MRP1, secondary metabolites, review

Introduction

Evolutionary and ecological background

Plants are sessile organisms which cannot run away when attacked by an herbivore nor do they have an immune system to combat infesting parasites, bacteria, fungi, or viruses. From early days of the evolution of land plants they had to cope with these environmental challenges. Plants developed a number of mechanical traits, such as resistant epidermal and bark tissues but also spines and thorns as defense tools. In addition, plants evolved a high diversity of defense chemicals, the so-called secondary metabolites (SM; Table Table1).1). Besides defense, some SM function as signal compounds or protect against oxidative or UV stress (Wink, 1988, 2003, 2008b, 2010a,b).

Table 1
Structural types of secondary metabolites and known structures.

The structures of SM have been optimized during evolution in such a way that they can interfere with molecular targets in herbivores and microbes. The main group of targets include (1) proteins, (2) DNA, RNA, and (3) the biomembrane (Wink, 2008a,b; Wink and Schimmer, 2010). Neuronal signal transduction is a central and specific target in animals and many SM, especially alkaloids and amines are directed toward it (Wink, 1993, 2000). SM which interfere with proteins, such as polyphenols, biomembranes (saponins and other lipophilic terpenoids), or DNA (alkylating or intercalating mutagens) affect a wider range of organisms, including animals and microbes. In general, membrane and DNA active SM have cytotoxic properties. Affected cells usually undergo apoptosis (Wink, 2007). Several SM interfere with the neuronal signal transduction in animals and are thus potent neurotoxins (Wink, 1993, 2000).

A large number of SM have lipophilic properties which enable them to readily pass biomembranes in target organisms by simple diffusion. These SM are also dangerous for the producing plants. Therefore, they are usually stored in dead tissue away from living cells, such as resin ducts, oil cells, trichomes, or cuticles (Wink, 2010b). The absorption of polar SM is usually slower or does not take place at all, with the exception of SM that can use transporters for sugars or amino acids or endocytosis as a kind of “stowaway.” Furthermore, SM usually occur in complex mixtures which may contain SM (such as saponins) that can facilitate the uptake of polar SM (Hebestreit and Melzig, 2003).

The response of herbivores and pathogens against plant defense chemicals

In the evolutionary arms race herbivores and microbes evolved mechanisms to avoid or inactivate the defense chemistry of plants. Mechanisms of resistance in animals and humans are complex and often multifactorial. Mechanisms include: (1) Activation of ATP-binding cassette (ABC) transporters, such as p-gp, which pump out lipophilic compounds that have entered a cell, (2) activation of cytochrome p450 oxidases (CYP) which can oxidize lipophilic agents to make them more hydrophilic and accessible for conjugation reaction with glucuronic acid, sulfate, or amino acids, and (3) activation of glutathione transferase (GST), which can conjugate xenobiotics with glutathione. The reactions of CYP, GST, and conjugation are well known in pharmacology and categorized as phase I and phase II reactions. These reactions are important in the metabolism of medicinal drugs and toxins. This evolutionary history also applies for humans which enables us to metabolize a large number of xenobiotics.

In phase I, a lipophilic SM is made more hydrophilic by introducing hydroxyl groups. This reaction is catalyzed by CYP and CYP1A1, CYP1A2, CYP3A4, and CYP2D6 are the most important enzymes. Furthermore, these CYP can cleave N-methyl, O-methyl, or methylene groups in order to obtain a more hydrophilic or better accessible substrate (Guengerich, 2001). In the human genome, about 57 active CYP genes are known (Ingelman-Sundberg and Gomez, 2010). A substantial polymorphism of CYPs exists which enables them to metabolize a wide range of xenobiotics. The regulation of the corresponding genes is only partly known. The genes encoding these enzymes, which occur in intestinal epithelia and in the liver, are inducible by SM that have entered the body. In phase II, the hydroxylated xenobiotics are conjugated with polar molecules, such as glutathione, sulfate, or glucuronic acid. These conjugates are eliminated via the kidneys and urine. That means, on exposure to lipophilic SM, genes which encode these enzymes are often induced and that activation can inactivate the toxins. Several SM carry methylenedioxy groups on their phenolic rings, such as in the isoquinoline alkaloids berberine and hydrastine, which are assumed to be inhibitors of CYP (Wink, 2007). Alkaloids which can inhibit CYP have been summarized by Wink (2007).

Resistance mechanisms in bacterial pathogens are even more evident because several pathogens already have evolved resistance against medicinally used antibiotics. The main mechanisms include:

  • Direct inactivation of the antibiotic, e.g., by cleavage of the beta-lactam ring of penicillin by beta-lactams or acetylation, methylation of other antibiotics
  • Target site modification: molecular change of the target molecule (proteins, rRNA) in such a way that the antibiotic cannot bind any longer
  • Bypass or alteration of metabolic pathways in cases where an antibiotic blocks a pathway (e.g., as for sulfonamides)
  • Prevention of drug uptake
  • Export out of the cell by ABC transporters so that the intracellular concentration of an antibiotic (e.g., tetracycline) are reduced. In Bacteria, this is one of several factors responsible for multidrug resistance (MDR).

ABC Transporter

Resistance against defense chemicals can be obtained through the expression of ABC transporters that are present in most cells and organisms. They are especially active in epithelia of intestinal, liver, kidney, and endothelia (Twentyman and Bleehen, 1991; Nielsen and Skovsgaard, 1992; Nooter and Stoter, 1996; Steinbach et al., 2002; You and Morris, 2007).

Three types of ABC transporters have been studied in detail:

  1. P-glycoprotein (P-gp; molecular weight 170 kD) or MDR1 protein (multiple drug resistance protein) was the first cloned ABC transporter. It is encoded by the ABCB1 gene. P-gp is composed of two similar moieties and each half contains one transmembrane and one ATP-binding domain. P-gp is an efflux pump directed to the gut lumen. The substrate molecules bind to transmembrane domains and then are exported to extracellular space, driven by the energy of ATP hydrolysis. A wide range of lipophilic chemotherapeutical agents, such as anthracenes, anthracyclines, epipodophyllotoxins, taxanes, and Vinca alkaloids, which can enter tumor cells by free diffusion, are substrates of P-gp and can be extruded by the transporter (Loo and Clarke, 2005).
  2. Multiple resistance-associated protein 1 (MRP1; 190 kD) is encoded by the ABCC1 gene. MRP1 transports drugs conjugated to glutathione (GSH), and also unmodified therapeutics in the presence of GSH (van der Kolk et al., 1999). MRP1 is structurally similar to P-gp, and can expel anthracenedione, anthracycline, epipodophyllotoxin, Vinca alkaloids, etc. (Wijnholds et al., 2000).
  3. Breast cancer resistance protein (BCRP; 72 kD) is the product of the ABCG2 gene. It has one transmembrane domain and one ATP-binding domain and only functions after dimerization. BCRP confers resistance to doxorubicin, camptothecin, and mitoxantrone (Ambudkar et al., 1999; Schinkel and Jonker, 2003; Mao and Unadkat, 2005; Krishnamurthy and Schuetz, 2006).

Breast cancer resistance protein and P-gp are highly expressed at the apical membrane of blood–brain barrier (BBB), placenta, liver, intestine, and other organs (Schinkel and Jonker, 2003). These ATP-driven transporters can pump lipophilic compounds out of the cell, either back to the gut lumen or into the blood system, thus reducing the intracellular concentration of potentially toxic compounds.

ATP-binding cassette transporters are also important at the BBB. The BBB only allows the entry of small lipophilic substances by passive diffusion. However, the uptake of lipophilic compounds in the brain is relatively low due to the high activity of P-gp, MRP, and organic anion transporting polypeptides (OATPs). These transporters catalyze a rapid efflux of lipophilic xenobiotics from the CNS (Elsinga et al., 2004; Mahringer and Fricker, 2010).

Multidrug resistance was discovered during chemotherapy of cancer patients who developed resistance against a cytotoxic drug. It transpired that the tumor cells were able to pump out the lipophilic alkaloids (such as Vinca alkaloids, taxanes, and anthracycline derivatives) at almost the same speed as they were entering the tumor cells. Activated cells became resistant to vincristine but also to several other lipophilic drugs. This means that a cross-resistance or MDR had occurred. As a consequence, a major obstacle to the successful chemotherapy of tumors is MDR. Upon exposure to xenobiotics MDR genes can become upregulated. Overexpressed ABC transporters (P-gp, MRP1, or BCRP) can mediate resistance of tumor cells against a variety of anticancer drugs (Schinkel and Jonker, 2003). This phenomenon is called MDR, which is one of the most important reasons of chemotherapy failure (Gottesman, 2002).

Several of human protozoal parasites (Plasmodium, Leishmania, Trypanosoma) can develop resistance against prophylactic and therapeutic agents, such as quinolines, naphthoquinones, sesquiterpene lactones, and others. The underlying mechanism includes membrane glycoproteins that are orthologous to human P-gp. These ABC transporters can also be induced and activated.

ATP-binding cassette transporters are also present in bacteria and fungi in which they confer resistance to antibiotics and fungicidal compounds (Steffens et al., 1996). A medicinally important issue is the increasing resistance of bacteria toward antibiotics, and ABC transporters can be involved in bacterial MDR (besides other mechanisms discussed above). Apparently, ABC transporters are an old invention of nature, which occur from E. coli to Homo sapiens.

Overcoming Resistance Caused by ABC Transporters

Multidrug resistance reversal agents are also called chemosensitizers or modulators. They can inhibit the efflux activity of transporters and other relevant MDR targets (see above); in consequence they can potentiate cytotoxicity, and are therefore important alternatives to overcome MDR (Watanabe et al., 1995; Dantzig et al., 1996; Robert and Jarry, 2003).

Multi-resistant tumor cells frequently express different ABC transporters simultaneously, e.g., P-gp, MRP1, BCRP, and others (Annereau et al., 2004; Gillet et al., 2004). Because the substrate spectra of ABC transporters only partly overlap, co-expression of transporters might produce more diverse resistance profiles than those of any one member alone. Thus broad-spectrum reversal agents are needed and some compounds exhibit this property (Hyafil et al., 1993; Maliepaard et al., 2001; Brooks et al., 2003).

A number of natural or synthetic compounds have been discovered that can inhibit P-gp and re-sensitize resistant tumor cells in vitro (Chauffert et al., 1990; Genne et al., 1992; He and Liu, 2002; Wink, 2007). Although these agents work successfully in some patients, most results of clinical trials were disappointing (Solary et al., 2000; Dantzig et al., 2001). Some of these reversal agents did not work in vivo or some had too severe side effects. Therefore, new and better reversal agents are still needed.

Most modulators of ABC transporters act by binding to membrane transport proteins (especially P-gp, MRP1, and BCRP) as competitive inhibitors, or by indirect mechanisms related to phosphorylation of the transport proteins, or the expression of the mdr1 and mrp1 genes. Other inhibitors not only act at the level of the transporter gene but influence their expression; for example, the alkaloid piperine lowered the expression levels of ABCB1, ABCC1, and ABCG2 genes which encode P-gp, MRP1, and BCRP (Li et al., 2011b).

Inhibitors of ABC Transporters from Plants

For this review we carried out a comprehensive literature research. Table Table22 summarizes the search results for SM from plants, which can serve as ABC transporter substrates and might be useful in strategies to reverse drug resistance in cancer cells, fungi, and parasites. Compounds affecting other resistance mechanisms, which are important and which were discussed above, were not considered in this review.

Table 2
Secondary metabolites from plants that can inhibit P-gp, MRP1, BCRP, bacterial, and fungal ABC transporters.

Lipophilic SM, such as monoterpenes, diterpenes, triterpenes (including saponins), steroids (including cardiac glycosides), and tetraterpenes (carotenoids; Table Table2)2) function as substrates for P-gp in cancer cells. The ABC transporter from fungi, AtrB (Andrade et al., 2000), or the NorA efflux pump in Staphylococcus aureus can also be affected (Smith et al., 2007). Because of their lipophilicity, these terpenoids most likely are substrates for P-gp and other ABC transporter. If administered as a chemosensitizer in combination with a cytotoxic agent they function as inhibitors competing for binding to the active side of the transporters.

Among the structurally heterogenous group of alkaloids, a large number of the more lipophilic substances from the classes of isoquinoline, protoberberine, quinoline, indole, monoterpene indole, and steroidal alkaloids (Table (Table2)2) can serve as substrates whereas the more polar alkaloids with a tropane, quinolizidine, piperidine, and pyrrolizidine skeleton do not bind to ABC transporters (Wink, 2007). Similar to the situation of terpenoids, the active alkaloids probably function as competitive inhibitors of P-gp and BCRP in cancer cells, and NorA in bacteria and fungi (Table (Table22).

It is remarkable on the first sight that also quite a large number of more polar phenolic SM (phenolic acids, flavonoids, catechins, chalcones, xanthones, stilbenes, anthocyanins, tannins, anthraquinones, and naphthoquinones) inhibit P-gp, MRP1, BCRP, and OATP in cancer cells with MDR. Some of them can reverse MDR when given in combination with cytotoxic agents (Table (Table2).2). Bacteria and fungi appear to be sensitive as well (Guz et al., 2001; Falcao-Silva et al., 2009). Some of these phenolics are lipophilic enough to be competitive inhibitors of ABC transporters.

Polyphenols are exciting tethering compounds of proteins. They can effectively interact directly with proteins by forming hydrogen and ionic bonds with amino acid side chains. They can thus interfere with the 3D structure of proteins (conformation) and inhibit their activities (details in Wink, 2008b; Wink and Schimmer, 2010). We speculate therefore, that the inhibition seen in polyphenols is caused by a direct binding and complex formation (not necessarily the active side) of ABC transporters. Since many polyphenols have no or very low toxicity (e.g., many of them are ingredients of our food, such as flavonoids or tannins), they might be excellent candidates as reversal agents, both in chemotherapy and in agriculture.

We have focused on ABC transporters in this review. But as mentioned above, resistance can be due to other mechanisms as well and is often multifactorial. Faria et al. (2011) and Kim et al. (2007, 2010) have successfully employed thymol (a phenolic monoterpene), salicyl aldehyde, and the alkaloid berberine to enhance the activity of fungicides in Candida, Aspergillus, Penicillium, and Cryptococcus. These experimental data can be regarded as a proof of concept that plant secondary products can be interesting candidates for chemosensitization (even if they not interfere with ABC transporters) of pathogenic fungi in agriculture and food technology to improve the fungicidal activity of certain fungicides.

Conclusion

This review summarizes the evidence that selected SM of plants can be interesting candidates to inhibit ABC transporters in MDR cancer cells or to chemosensitize pathogenic fungi and other microbes for treatment with antimicrobial agents. Whereas lipophilic terpenoids and alkaloids appear to be substrates of P-gp, MRP1, or BCRP and thus competitive inhibitors, the more polar phenolic compounds (flavonoids, tannins, quinones) can bind to the transporter proteins and inhibit their activity by disturbing protein conformation. A combination of a cytotoxic agent, antibiotic, or fungicide with a natural chemosensitizer (not necessarily an inhibitor of ABC transporters) might provide an interesting strategy to overcome MDR in cancer patients and to improve antibiotic or antifungal efficacy in medicine, agriculture, or food industry.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Abbreviations

ABC, ATP-binding cassette; BCRP, breast cancer resistance protein; MDR, multidrug resistance; MRP1, multidrug resistance-associate protein; P-gp, P-glycoprotein.

References

  • Adams M., Mahringer A., Kunert O., Fricker G., Efferth T., Bauer R. (2007). Cytotoxicity and p-glycoprotein modulating effects of quinolones and indoloquinazolines from the Chinese herb Evodia rutaecarpa. Planta Med. 73, 1554–1557.10.1055/s-2007-990261 [PubMed] [Cross Ref]
  • Agarwal R., Agarwal C., Ichikawa H., Singh R. P., Aggarwal B. B. (2006). Anticancer potential of silymarin, from bench to bed side. Anticancer Res. 26, 4457–4498. [PubMed]
  • Ambudkar S. V., Dey S., Hrycyna C. A., Ramachandra M., Pastan I., Gottesman M. M. (1999). Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39, 361–398.10.1146/annurev.pharmtox.39.1.361 [PubMed] [Cross Ref]
  • An G., Wu F., Morris M. E. (2011). 5,7-Dimethoxyflavone and multiple flavonoids in combination alter the ABCG2-mediated tissue distribution of mitoxantrone in mice. Pharm. Res. 28, 1090–1099.10.1007/s11095-011-0368-y [PubMed] [Cross Ref]
  • Andrade A. C., Del Sorbo G., Van Nistelrooy J. G., Waard M. A. (2000). The ABC transporter AtrB from Aspergillus nidulans mediates resistance to all major classes of fungicides and some natural toxic compounds. Microbiology 146, 1987–1997. [PubMed]
  • Angelini A., Di Ilio C., Castellani M. L., Conti P., Cuccurullo F. (2010). Modulation of multidrug resistance p-glycoprotein activity by flavonoids and honokiol in human doxorubicin- resistant sarcoma cells (MES-SA/DX-5), implications for natural sedatives as chemosensitizing agents in cancer therapy. J. Biol. Regul. Homeost. Agents 24, 197–205. [PubMed]
  • Annereau J. P., Szakács G., Tucker C. J., Arciello A., Cardarelli C., Collins J., Grissom S., Zeeberg B. R., Reinhold W., Weinstein J. N., Pommier Y., Paules R. S., Gottesman M. M. (2004). Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance. Mol. Pharmacol. 66, 1397–1405.10.1124/mol.104.005009 [PubMed] [Cross Ref]
  • Arora A., Shukla Y. (2003). Modulation of vinca-alkaloid induced P-glycoprotein expression by indole-3-carbinol. Cancer Lett. 189, 167–173.10.1016/S0304-3835(02)00550-5 [PubMed] [Cross Ref]
  • Beck W. T., Cirtain M. C., Glover C. J., Felsted R. L., Safa A. R. (1988). Effects of indole alkaloids on multidrug resistance and labeling of P-glycoprotein by a photoaffinity analog of vinblastine. Biochem. Biophys. Res. Commun. 153, 959–966.10.1016/S0006-291X(88)81321-4 [PubMed] [Cross Ref]
  • Belofsky G., Percivill D., Lewis K., Tegos G. P., Ekart J. (2004). Phenolic metabolites of Dalea versicolor that enhance antibiotic activity against model pathogenic bacteria. J. Nat. Prod. 67, 481–484.10.1021/np030409c [PubMed] [Cross Ref]
  • Berek L., Szabo D., Petri I. B., Shoyama Y., Lin Y. H., Molnar J. (2001). Effects of naturally occurring glucosides, solasodine glucosides, ginsenosides and parishin derivatives on multidrug resistance of lymphoma cells and leukocyte functions. In vivo 15, 151–156. [PubMed]
  • Bhardwaj R. K., Glaeser H., Becquemont L., Klotz U., Gupta S. K., Fromm M. F. (2002). Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J. Pharmacol. Exp. Ther. 302, 645–650.10.1124/jpet.102.034728 [PubMed] [Cross Ref]
  • Bhat U. G., Winter M. A., Pearce H. L., Beck W. T. (1995). A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdr1 and P-glycoprotein in a human colon carcinoma cell line. Mol. Pharmacol. 48, 682–689. [PubMed]
  • Brooks T. A., Minderman H., O’Loughlin K. L., Pera P., Ojima I., Baer M. R., Bernacki R. J. (2003). Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol. Cancer Ther. 2, 1195–1205. [PubMed]
  • Cavet M. E., West M., Simmons N. L. (1996). Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells. Br. J. Pharmacol. 118, 1389–1396. [PMC free article] [PubMed]
  • Chanmahasathien W., Ampasavate C., Greger H., Limtrakul P. (2011). Stemona alkaloids, from traditional Thai medicine, increase chemosensitivity via P-glycoprotein-mediated multidrug resistance. Phytomedicine 18, 199–204.10.1016/j.phymed.2010.07.014 [PubMed] [Cross Ref]
  • Chauffert B., Pelletier H., Corda C., Solary E., Bedenne L., Caillot D., Martin F. (1990). Potential usefulness of quinine to circumvent the anthracycline resistance in clinical practice. Br. J. Cancer 62, 395–397.10.1038/bjc.1990.305 [PMC free article] [PubMed] [Cross Ref]
  • Chen G., Ramachandran C., Krishan A. (1993). Thaliblastine, a plant alkaloid, circumvents multidrug resistance by direct binding to P-glycoprotein. Cancer Res. 53, 2544–2547. [PubMed]
  • Chen G., Teicher B. A., Frei E. (1996). Differential interactions of Pgp inhibitor thaliblastine with adriamycin, etoposide, taxol and anthrapyrazole CI941 in sensitive and multidrug-resistant human MCF-7 breast cancer cells. Anticancer Res. 16, 3499–3505. [PubMed]
  • Chen G., Waxman D. J. (1995). Complete reversal by thaliblastine of 490-fold adriamycin resistance in multidrug-resistant (MDR) human breast cancer cells. Evidence that multiple biochemical changes in MDR cells need not correspond to multiple functional determinants for drug resistance. J. Pharmacol. Exp. Ther. 274, 1271–1277. [PubMed]
  • Chieli E., Romiti N., Rodeiro I., Garrido G. (2010). In vitro modulation of ABCB1/P-glycoprotein expression by polyphenols from Mangifera indica. Chem. Biol. Interact. 186, 287–294.10.1016/j.cbi.2010.05.012 [PubMed] [Cross Ref]
  • Choi C. H., Kang G., Min Y. D. (2003). Reversal of P-glycoprotein-mediated multidrug resistance by protopanaxatriol ginsenosides from Korean red ginseng. Planta Med. 69, 235–240.10.1590/S0034-72992003000200014 [PubMed] [Cross Ref]
  • Choi S. U., Park S. H., Kim K. H., Choi E. J., Kim S., Park W. K., Zhang Y. H., Kim H. S., Jung N. P., Lee C. O. (1998). The bisbenzylisoquinoline alkaloids, tetrandine and fangchinoline, enhance the cytotoxicity of multidrug resistance-related drugs via modulation of P-glycoprotein. Anticancer Drugs 9, 255–261.10.1097/00001813-199803000-00008 [PubMed] [Cross Ref]
  • Chung S. Y., Sung M. K., Kim N. H., Jang J. O., Go E. J., Lee H. J. (2005). Inhibition of P-glycoprotein by natural products in human breast cancer cells. Arch. Pharm. Res. 28, 823–828.10.1007/BF02972972 [PubMed] [Cross Ref]
  • Chusri S., Villanueva I., Voravuthikunchai S. P., Davies J. (2009). Enhancing antibiotic activity, a strategy to control Acinetobacter infections. J. Antimicrob. Chemother. 64, 1203–1211.10.1093/jac/dkp381 [PubMed] [Cross Ref]
  • Conseil G., Baubichon-Cortay H., Dayan G., Jault J. M., Barron D., Di Pietro A. (1998). Flavonoids, a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. Proc. Natl. Acad. Sci. U.S.A. 95, 9831–9836.10.1073/pnas.95.17.9831 [PMC free article] [PubMed] [Cross Ref]
  • Cooray H. C., Janvilisri T., van Veen H. W., Hladky S. B., Barrand M. A. (2004). Interaction of the breast cancer resistance protein with plant polyphenols. Biochem. Biophys. Res. Commun. 317, 269–275.10.1016/j.bbrc.2004.03.040 [PubMed] [Cross Ref]
  • Critchfield J. W., Welsh C. J., Phang J. M., Yeh G. C. (1994). Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Activation of P-glycoprotein as a putative mechanism. Biochem. Pharmacol. 48, 1437–1445.10.1016/0006-2952(94)90568-1 [PubMed] [Cross Ref]
  • Cui X. R., Tsukada M., Suzuki N., Shimamura T., Gao L., Koyanagi J., Komada F., Saito S. (2008). Comparison of the cytotoxic activities of naturally occurring hydroxyanthraquinones and hydroxynaphthoquinones. Eur. J. Med. Chem. 43, 1206–1215.10.1016/j.ejmech.2007.08.009 [PubMed] [Cross Ref]
  • Dantzig A. H., Law K. L., Cao J., Starling J. J. (2001). Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic. Curr. Med. Chem. 8, 39–50. [PubMed]
  • Dantzig A. H., Shepard R. L., Cao J., Law K. L., Ehlhardt W. J., Baughman T. M., Bumol T., Starling J. J. (1996). Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res. 56, 4171–4179. [PubMed]
  • de Castro W. V., Mertens-Talcott S., Derendorf H., Butterweck V. (2007). Grapefruit juice-drug interactions, grapefruit juice and its components inhibit P-glycoprotein (ABCB1) mediated transport of talinolol in Caco-2 cells. J. Pharm. Sci. 96, 2808–2817.10.1002/jps.20975 [PubMed] [Cross Ref]
  • de Castro W. V., Mertens-Talcott S., Derendorf H., Butterweck V. (2008). Effect of grapefruit juice, naringin, naringenin, and bergamottin on the intestinal carrier-mediated transport of talinolol in rats. J. Agric. Food Chem. 56, 4840–4845.10.1021/jf0728451 [PubMed] [Cross Ref]
  • de Lannoy I. A., Silverman M. (1992). The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem. Biophys. Res. Commun. 189, 551–557.10.1016/0006-291X(92)91593-F [PubMed] [Cross Ref]
  • de Wet H., McIntosh D. B., Conseil G., Baubichon-Cortay H., Krell T., Jault J. M., Daskiewicz J. B., Barron D., Di Pietro A. (2001). Sequence requirements of the ATP-binding site within the C-terminal nucleotide-binding domain of mouse P-glycoprotein, structure-activity relationships for flavonoid binding. Biochemistry 40, 10382–10391.10.1021/bi010657c [PubMed] [Cross Ref]
  • Ding Z., Tang S. C., Weerasinghe P., Yang X., Pater A., Liepins A. (2002). The alkaloid sanguinarine is effective against multidrug resistance in human cervical cells via bimodal cell death. Biochem. Pharmacol. 63, 1415–1421.10.1016/S0006-2952(02)00902-4 [PubMed] [Cross Ref]
  • Distefano M., Scambia G., Ferlini C., Gaggini C., De Vincenzo R., Riva A., Bombardelli E., Ojima I., Fattorossi A., Panici P. B., Mancuso S. (1997). Anti-proliferative activity of a new class of taxanes (14beta-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells. Int. J. Cancer 72, 844–850.10.1002/(SICI)1097-0215(19970904)72:5<844::AID-IJC22>3.0.CO;2-7 [PubMed] [Cross Ref]
  • Dorr R. T., Liddil J. D., Von Hoff D. D., Soble M., Osborne C. K. (1989). Antitumor activity and murine pharmacokinetics of parenteral acronycine. Cancer Res. 49, 340–344. [PubMed]
  • Duarte N., Gyemant N., Abreu P. M., Molnar J., Ferreira M. J. (2006). New macrocyclic lathyrane diterpenes, from Euphorbia lagascae, as inhibitors of multidrug resistance of tumour cells. Planta Med. 72, 162–168.10.1055/s-2005-873196 [PubMed] [Cross Ref]
  • Duarte N., Lage H., Abrantes M., Ferreira M. J. (2010). Phenolic compounds as selective antineoplasic agents against multidrug-resistant human cancer cells. Planta Med. 76, 975–980.10.1055/s-0029-1240892 [PubMed] [Cross Ref]
  • Duarte N., Ramalhete C., Varga A., Molnar J., Ferreira M. J. (2009). Multidrug resistance modulation and apoptosis induction of cancer cells by terpenic compounds isolated from Euphorbia species. Anticancer Res. 29, 4467–4472. [PubMed]
  • Efferth T., Chen Z., Kaina B., Ag W. (2005). Molecular determinants of response of tumor cells to berberine. Cancer Genomics Proteomics 2, 115–123.
  • Efferth T., Sauerbrey A., Halatsch M. E., Ross D. D., Gebhart E. (2003). Molecular modes of action of cephalotaxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines. Naunyn Schmiedebergs Arch. Pharmacol. 367, 56–67.10.1007/s00210-002-0632-0 [PubMed] [Cross Ref]
  • El-Readi M. Z., Hamdan D., Farrag N., El-Shazly A., Wink M. (2010). Inhibition of P-glycoprotein activity by limonin and other secondary metabolites from Citrus species in human colon and leukaemia cell lines. Eur. J. Pharmacol. 626, 139–145.10.1016/j.ejphar.2009.09.040 [PubMed] [Cross Ref]
  • Elsinga P. H., Hendrikse N. H., Bart J., Vaalburg W., van Waarde A. (2004). PET studies on P-glycoprotein function in the blood-brain barrier, how it affects uptake and binding of drugs within the CNS. Curr. Pharm. Des. 10, 1493–1503.10.2174/1381612043384736 [PubMed] [Cross Ref]
  • Etheridge A. S., Black S. R., Patel P. R., So J., Mathews J. M. (2007). An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal, Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents. Planta Med. 73, 731–741.10.1055/s-2007-981550 [PubMed] [Cross Ref]
  • Falcao-Silva V. S., Silva D. A., Souza Mde F., Siqueira-Junior J. P. (2009). Modulation of drug resistance in Staphylococcus aureus by a kaempferol glycoside from Herissantia tiubae (Malvaceae). Phytother. Res. 23, 1367–1370.10.1002/ptr.2695 [PubMed] [Cross Ref]
  • Faria N. C. G., Kim J. H., Goncalves L., Martins M., Chan K. L., Campbell B. (2011). Enhanced activity of antifungal drugs using natural phenolics against yeast strains of Candida and Cryptococcus. Lett. Appl. Micobiol. 5, 506–513.10.1111/j.1472-765X.2011.03032.x [PubMed] [Cross Ref]
  • Fernandes J., Castilho R. O., da Costa M. R., Wagner-Souza K., Coelho Kaplan M. A., Gattass C. R. (2003). Pentacyclic triterpenes from Chrysobalanaceae species, cytotoxicity on multidrug resistant and sensitive leukemia cell lines. Cancer Lett. 190, 165–169.10.1016/S0304-3835(02)00593-1 [PubMed] [Cross Ref]
  • Foster B. C., Foster M. S., Vandenhoek S., Krantis A., Budzinski J. W., Arnason J. T., Gallicano K. D., Choudri S. (2001). An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J. Pharm. Pharm. Sci. 4, 176–184. [PubMed]
  • Fu L., Liang Y., Deng L., Ding Y., Chen L., Ye Y., Yang X., Pan Q. (2004). Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Chemother. Pharmacol. 53, 349–356.10.1007/s00280-003-0742-5 [PubMed] [Cross Ref]
  • Fu L. W., Zhang Y. M., Liang Y. J., Yang X. P., Pan Q. C. (2002) , The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenografts derived from human breast adenocarcinoma MCF-7/adr cells. Eur. J. Cancer 38, 418–426.10.1016/S0959-8049(01)00356-2 [PubMed] [Cross Ref]
  • Genne P., Dimanche-Boitrel M. T., Mauvernay R. Y., Gutierrez G., Duchamp O., Petit J. M., Martin F., Chauffert B. (1992). Cinchonine, a potent efflux inhibitor to circumvent anthracycline resistance in vivo. Cancer Res. 52, 2797–2801. [PubMed]
  • Genne P., Duchamp O., Solary E., Pinard D., Belon J. P., Dimanche-Boitrel M. T., Chauffert B. (1994). Comparative effects of quinine and cinchonine in reversing multidrug resistance on human leukemic cell line K562/ADM. Leukemia 8, 160–164. [PubMed]
  • Gibbons S., Leimkugel J., Oluwatuyi M., Heinrich M. (2003). Activity of Zanthoxylum clava-herculis extracts against multi-drug resistant methicillin-resistant Staphylococcus aureus (mdr-MRSA). Phytother. Res. 17, 274–275.10.1002/ptr.1112 [PubMed] [Cross Ref]
  • Gibbons S., Udo E. E. (2000). The effect of reserpine, a modulator of multidrug efflux pumps, on the in vitro activity of tetracycline against clinical isolates of methicillin resistant Staphylococcus aureus (MRSA) possessing the tet(K) determinant. Phytother. Res. 14, 139–140.10.1002/(SICI)1099-1573(200003)14:2<139::AID-PTR608>3.3.CO;2-# [PubMed] [Cross Ref]
  • Gillet J. P., Efferth T., Steinbach D., Hamels J., de Longueville F., Bertholet V., Remacle J. (2004). Microarray-based detection of multidrug resistance in human tumor cells by expression profiling of ATP-binding cassette transporter genes. Cancer Res. 64, 8987–8993.10.1158/0008-5472.CAN-04-1978 [PubMed] [Cross Ref]
  • Gottesman M. M. (2002). Mechanisms of cancer drug resistance. Annu. Rev. Med. 53, 615–627.10.1146/annurev.med.53.082901.103929 [PubMed] [Cross Ref]
  • Guengerich F. P. (2001). Uncommon P450-catalyzed reactions. Curr. Drug Metab. 2, 93–115.10.2174/1389200013338694 [PubMed] [Cross Ref]
  • Guo X. L., Leng P., Yang Y., Yu L. G., Lou H. X. (2008). Plagiochin E, a botanic-derived phenolic compound, reverses fungal resistance to fluconazole relating to the efflux pump. J. Appl. Microbiol. 104, 831–838.10.1111/j.1365-2672.2007.03617.x [PubMed] [Cross Ref]
  • Guz N. R., Stermitz F. R., Johnson J. B., Beeson T. D., Willen S., Hsiang J., Lewis K. (2001). Flavonolignan and flavone inhibitors of a Staphylococcus aureus multidrug resistance pump, structure-activity relationships. J. Med. Chem. 44, 261–268.10.1021/jm0004190 [PubMed] [Cross Ref]
  • Gyemant N., Tanaka M., Antus S., Hohmann J., Csuka O., Mandoky L., Molnar J. (2005). In vitro search for synergy between flavonoids and epirubicin on multidrug-resistant cancer cells. In vivo 19, 367–374. [PubMed]
  • Gyemant N., Tanaka M., Molnar P., Deli J., Mandoky L., Molnar J. (2006) , Reversal of multidrug resistance of cancer cells in vitro, modification of drug resistance by selected carotenoids. Anticancer Res. 26, 367–374. [PubMed]
  • Han Y., Chin Tan T. M., Lim L. Y. (2008). In vitro and in vivo evaluation of the effects of piperine on P-gp function and expression. Toxicol. Appl. Pharmacol. 230, 283–289.10.1016/j.taap.2008.02.026 [PubMed] [Cross Ref]
  • He L., Liu G. Q. (2002). Effects of various principles from Chinese herbal medicine on rhodamine123 accumulation in brain capillary endothelial cells. Acta Pharmacol. Sin. 23, 591–596. [PubMed]
  • Hebestreit P., Melzig M. (2003). Cytotoxic activity of the seeds from Agrostemma githago var. githago. Planta Med. 69, 921–925.10.1055/s-2003-45101 [PubMed] [Cross Ref]
  • Hohmann J., Molnar J., Redei D., Evanics F., Forgo P., Kalman A., Argay G., Szabo P. (2002). Discovery and biological evaluation of a new family of potent modulators of multidrug resistance, reversal of multidrug resistance of mouse lymphoma cells by new natural jatrophane diterpenoids isolated from Euphorbia species. J. Med. Chem. 45, 2425–2431.10.1021/jm0111301 [PubMed] [Cross Ref]
  • Hou X. L., Takahashi K., Tanaka K., Tougou K., Qiu F., Komatsu K., Azuma J. (2008). Curcuma drugs and curcumin regulate the expression and function of P-gp in Caco-2 cells in completely opposite ways. Int. J. Pharm. 358, 224–229.10.1016/j.ijpharm.2008.03.010 [PubMed] [Cross Ref]
  • Hu X. F., Slater A., Wall D. M., Kantharidis P., Parkin J. D., Cowman A., Zalcberg J. R. (1995). Rapid up-regulation of mdr1 expression by anthracyclines in a classical multidrug-resistant cell line. Br. J. Cancer 71, 931–936.10.1038/bjc.1995.180 [PMC free article] [PubMed] [Cross Ref]
  • Hyafil F., Vergely C., Du Vignaud P., Grand-Perret T. (1993). In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 53, 4595–4602. [PubMed]
  • Ignacimuthu S., Shanmugam N. (2010). Antimycobacterial activity of two natural alkaloids, vasicine acetate and 2-acetyl benzylamine, isolated from Indian shrub Adhatoda vasica Nees. leaves. J. Biosci. 35, 565–570.10.1007/s12038-010-0065-8 [PubMed] [Cross Ref]
  • Ikeda R., Che X. F., Yamaguchi T., Ushiyama M., Zheng C. L., Okumura H., Takeda Y., Shibayama Y., Nakamura K., Jeung H. C. (2005). Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells. Cancer Sci. 96, 372–376.10.1111/j.1349-7006.2005.00057.x [PubMed] [Cross Ref]
  • Ingelman-Sundberg M., Gomez A. (2010). The past, present and future of pharmacoepigenomics. Pharmacogenomics 11, 625–662.10.2217/pgs.10.59 [PubMed] [Cross Ref]
  • Ivanova A., Serly J., Christov V., Stamboliyska B., Molnar J. (2011). Alkaloids derived from genus Veratrum and Peganum of Mongolian origin as multidrug resistance inhibitors of cancer cells. Fitoterapia 82, 570–575.10.1016/j.fitote.2010.10.012 [PubMed] [Cross Ref]
  • Ivanova A., Serly J., Dinchev D., Ocsovszki I., Kostova I., Molnar J. (2009). Screening of some saponins and phenolic components of Tribulus terrestris and Smilax excelsa as MDR modulators. In vivo 23, 545–550. [PubMed]
  • Jeong Y. H., Chung S. Y., Han A. R., Sung M. K., Jang D. S., Lee J., Kwon Y., Lee H. J., Seo E. K. (2007). P-glycoprotein inhibitory activity of two phenolic compounds, (-)-syringaresinol and tricin from Sasa borealis. Chem. Biodivers. 4, 12–16.10.1002/cbdv.200790001 [PubMed] [Cross Ref]
  • Kam T. S., Sim K. M., Pang H. S., Koyano T., Hayashi M., Komiyama K. (2004). Cytotoxic effects and reversal of multidrug resistance by ibogan and related indole alkaloids. Bioorg. Med. Chem. Lett. 14, 4487–4489.10.1016/j.bmcl.2004.06.074 [PubMed] [Cross Ref]
  • Kam T. S., Subramaniam G., Sim K. M., Yoganathan K., Koyano T., Toyoshima M., Rho M. C., Hayashi M., Komiyama K. (1998). Reversal of multidrug resistance (MDR) by aspidofractinine-type indole alkaloids. Bioorg. Med. Chem. Lett. 8, 2769–2772.10.1016/S0960-894X(98)00486-7 [PubMed] [Cross Ref]
  • Kars M. D., Iseri O. D., Gunduz U., Molnar J. (2008). Reversal of multidrug resistance by synthetic and natural compounds in drug-resistant MCF-7 cell lines. Chemotherapy 54, 194–200.10.1159/000140462 [PubMed] [Cross Ref]
  • Kashiwada Y., Nishimura K., Kurimoto S., Takaishi Y. (2011). New 29-nor-cycloartanes with a 3,4-seco- and a novel 2,3-seco-structure from the leaves of Sinocalycanthus chinensis. Bioorg. Med. Chem. 19, 2790–2796.10.1016/j.bmc.2011.03.055 [PubMed] [Cross Ref]
  • Katsui K., Kuroda M., Wang Y., Komatsu M., Himei K., Takemoto M., Akaki S., Asaumi J., Kanazawa S., Hiraki Y. (2004). Cepharanthine enhances adriamycin sensitivity by synergistically accelerating apoptosis for adriamycin-resistant osteosarcoma cell lines, SaOS2-AR and SaOS2 F-AR. Int. J. Oncol. 25, 47–56. [PubMed]
  • Kim J. H., Campbell B. C., Mahoney N., Chan K. L., Molyneux R. J. (2010). Chemosensitization of aflatoxigenic fungi to antimycin A and strobilurin using salicylaldehyde, a volatile natural compound targeting cellular antioxidation system. Mycopathologia 171, 291–298.10.1007/s11046-010-9356-8 [PubMed] [Cross Ref]
  • Kim J. H., Campbell B. C., Mahoney N., Chan K. L., Molyneux R. J., May G. (2007). Enhanced activity of strobilurin and fludioxonil by using berberine and phenolic compounds to target fungal antioxidative stress response. Lett. Appl. Microbiol. 45, 134–141.10.1111/j.1472-765X.2007.02159.x [PubMed] [Cross Ref]
  • Kitagawa S., Nabekura T., Nakamura Y., Takahashi T., Kashiwada Y. (2007). Inhibition of P-glycoprotein function by tannic acid and pentagalloylglucose. J. Pharm. Pharmacol. 59, 965–969.10.1211/jpp.59.7.0008 [PubMed] [Cross Ref]
  • Kolaczkowski M., Kolaczowska A., Luczynski J., Witek S., Goffeau A. (1998). In vivo characterization of the drug resistance profile of the major ABC transporters and other components of the yeast pleiotropic drug resistance network. Microb. Drug Resist. 4, 143–158.10.1089/mdr.1998.4.143 [PubMed] [Cross Ref]
  • Krishnamurthy P., Schuetz J. D. (2006). Role of ABCG2/BCRP in biology and medicine. Annu. Rev. Pharmacol. Toxicol. 46, 381–410.10.1146/annurev.pharmtox.46.120604.141238 [PubMed] [Cross Ref]
  • Kuete V., Ngameni B., Tangmouo J. G., Bolla J. M., Alibert-Franco S., Ngadjui B. T., Pages J. M. (2010). Efflux pumps are involved in the defense of Gram-negative bacteria against the natural products isobavachalcone and diospyrone. Antimicrob. Agents Chemother. 54, 1749–1752.10.1128/AAC.01533-09 [PMC free article] [PubMed] [Cross Ref]
  • Kurimoto S., Kashiwada Y., Lee K. H., Takaishi Y. (2011a). Triterpenes and a triterpene glucoside from Dysoxylum cumingianum. Phytochemistry 72, 2205–2211.10.1016/j.phytochem.2011.08.002 [PubMed] [Cross Ref]
  • Kurimoto S., Kashiwada Y., Morris-Natschke S. L., Lee K. H., Takaishi Y. (2011b). Dyscusins A-C, three new steroids from the leaves of Dysoxylum cumingianum. Chem. Pharm. Bull. 59, 1303–1306.10.1248/cpb.59.1303 [PubMed] [Cross Ref]
  • Lavie Y., Harel-Orbital T., Gaffield W., Liscovitch M. (2001). Inhibitory effect of steroidal alkaloids on drug transport and multidrug resistance in human cancer cells. Anticancer Res. 21, 1189–1194. [PubMed]
  • Lee S. W., Hwang B. Y., Kim S. E., Kim H. M., Kim Y. H., Lee K. S., Lee J. J., Ro J.-S. (1995). Isolation of modulators for multidrug resistance from the fruits of Evodia officinalis. Korean J. Physiol. Pharmacol. 26, 344–348.
  • Lee S. Y., Rhee Y. H., Jeong S. J., Lee H. J., Jung M. H., Kim S. H., Lee E. O., Ahn K. S. (2011). Hydrocinchonine, cinchonine, and qiuinidine potentiate paclitaxel-induced cytotoxicity and apoptosis via multidrug resistance reversal in MES-SA/DX5 uterine sarcoma cells. Environ. Toxicol. 26, 424–431.10.1002/tox.20568 [PubMed] [Cross Ref]
  • Lee Y.-J., Yamamoto K., Hamamoto H., Nakaune R., Hibi T. (2005). A novel ABC transporter gene ABC2 involved in multidrug susceptibility but not pathogenicity in rice blast fungus, Magnaporthe grisea. Pestic. Biochem. Physiol. 81, 13–23.10.1016/j.pestbp.2004.07.007 [Cross Ref]
  • Lee Y. S., Kang O. H., Choi J. G., Oh Y. C., Keum J. H., Kim S. B., Jeong G. S., Kim Y. C., Shin D. W., Kwon D. Y. (2010). Synergistic effect of emodin in combination with ampicillin or oxacillin against methicillin-resistant Staphylococcus aureus. Pharm. Biol. 48, 1285–1290.10.3109/13880201003770150 [PubMed] [Cross Ref]
  • Leslie E. M., Mao Q., Oleschuk C. J., Deeley R. G., Cole S. P. (2001). Modulation of multidrug resistance protein 1 (MRP1/ABCC1) transport and ATPase activities by interaction with dietary flavonoids. Mol. Pharmacol. 59, 1171–1180. [PubMed]
  • Li M. C., Yao Z., Takaishi Y., Tang S. A., Duan H. Q. (2011a). Isolation of novel phenolic compounds with multidrug resistance (MDR) reversal properties from Onychium japonicum. Chem. Biodivers. 8, 1112–1120.10.1002/cbdv.201000224 [PubMed] [Cross Ref]
  • Li S., Lei Y., Jia Y., Li N., Wink M., Ma Y. (2011b). Piperine, a piperidine alkaloid from Piper nigrum re-sensitizes P-gp, MRP1 and BCRP dependent multidrug resistant cancer cells. Phytomedicine 19, 83–87.10.1016/j.phymed.2011.06.031 [PubMed] [Cross Ref]
  • Limtrakul P., Chearwae W., Shukla S., Phisalphong C., Ambudkar S. V. (2007). Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Mol. Cell. Biochem. 296, 85–95.10.1007/s11010-006-9302-8 [PubMed] [Cross Ref]
  • Liu D. F., Li Y. P., Ou T. M., Huang S. L., Gu L. Q., Huang M., Huang Z. S. (2009). Synthesis and antimultidrug resistance evaluation of icariin and its derivatives. Bioorg. Med. Chem. Lett. 19, 4237–4240.10.1016/j.bmcl.2009.03.071 [PubMed] [Cross Ref]
  • Loo T. W., Clarke D. M. (2005). Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux. J. Membr. Biol. 206, 173–185.10.1007/s00232-005-0792-1 [PubMed] [Cross Ref]
  • Lu J. J., Cai Y. J., Ding J. (2012). The short-time treatment with curcumin sufficiently decreases cell viability, induces apoptosis and copper enhances these effects in multidrug-resistant K562/A02 cells. Mol. Cell. Biochem. 360, 253–260.10.1007/s11010-011-1064-2 [PubMed] [Cross Ref]
  • Ma Y., Wink M. (2008). Lobeline, a piperidine alkaloid from Lobelia can reverse P-gp dependent multidrug resistance in tumor cells. Phytomedicine 15, 754–758.10.1016/j.phymed.2007.11.015 [PubMed] [Cross Ref]
  • Ma Y., Wink M. (2009). “Reversal of multidrug resistance (MDR) by the isoquinoline alkaloid glaucine,” in Multiple Drug Resistance, eds Meszaros A., Balogh G., editors. (Hauppauge: Nova Science Publishers; ), 1–19.
  • Ma Y., Wink M. (2010). The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin. Phytother. Res. 24, 146–149.10.1002/ptr.2860 [PubMed] [Cross Ref]
  • Madureira A. M., Spengler G., Molnar A., Varga A., Molnar J., Abreu P. M., Ferreira M. J. (2004). Effect of cycloartanes on reversal of multidrug resistance and apoptosis induction on mouse lymphoma cells. Anticancer Res. 24, 859–864. [PubMed]
  • Mahringer A., Fricker G. (2010). BCRP at the blood-brain barrier, genomic regulation by 17β-estradiol. Mol. Pharm. 7, 1835–1847.10.1021/mp1001729 [PubMed] [Cross Ref]
  • Maliepaard M., van Gastelen M. A., Tohgo A., Hausheer F. H., van Waardenburg R. C., de Jong L. A., Pluim D., Beijnen J. H., Schellens J. H. (2001). Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin. Cancer Res. 7, 935–941. [PubMed]
  • Mao Q., Unadkat J. D. (2005). Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J. 7, E118–E133.10.1208/aapsj070112 [PMC free article] [PubMed] [Cross Ref]
  • Markham P. N., Westhaus E., Klyachko K., Johnson M. E., Neyfakh A. A. (1999). Multiple novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus. Antimicrob. Agents Chemother. 43, 2404–2408. [PMC free article] [PubMed]
  • Martins A., Vasas A., Schelz Z., Viveiros M., Molnar J., Hohmann J., Amaral L. (2010). Constituents of Carpobrotus edulis inhibit P-glycoprotein of MDR1-transfected mouse lymphoma cells. Anticancer Res. 30, 829–835. [PubMed]
  • Mattern M. R., Hofmann G. A., Polsky R. M., Funk L. R., McCabe F. L., Johnson R. K. (1993). In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells. Oncol. Res. 5, 467–474. [PubMed]
  • Mei Y., Qian F., Wei D., Liu J. (2004). Reversal of cancer multidrug resistance by green tea polyphenols. J. Pharm. Pharmacol. 56, 1307–1314.10.1211/0022357044364 [PubMed] [Cross Ref]
  • Meschini S., Marra M., Calcabrini A., Federici E., Galeffi C., Arancia G. (2003). Voacamine, a bisindolic alkaloid from Peschiera fuchsiaefolia, enhances the cytotoxic effect of doxorubicin on multidrug-resistant tumor cells. Int. J. Oncol. 23, 1505–1513. [PubMed]
  • Meschini S., Marra M., Condello M., Calcabrini A., Federici E., Dupuis M. L., Cianfriglia M., Arancia G. (2005). Voacamine, an alkaloid extracted from Peschiera fuchsiaefolia, inhibits P-glycoprotein action in multidrug-resistant tumor cells. Int. J. Oncol. 27, 1597–1603. [PubMed]
  • Michalet S., Cartier G., David B., Mariotte A. M., Dijoux-Franca M. G., Kaatz G. W., Stavri M., Gibbons S. (2007). N-caffeoylphenalkylamide derivatives as bacterial efflux pump inhibitors. Bioorg. Med. Chem. Lett. 17, 1755–1758. [PubMed]
  • Min Y. D., Choi S. U., Lee K. R. (2006a). Aporphine alkaloids and their reversal activity of multidrug resistance (MDR) from the stems and rhizomes of Sinomenium acutum. Arch. Pharm. Res. 29, 627–632.10.1007/BF02968246 [PubMed] [Cross Ref]
  • Min Y. D., Yang M. C., Lee K. H., Kim K. R., Choi S. U., Lee K. R. (2006b). Protoberberine alkaloids and their reversal activity of P-gp expressed multidrug resistance (MDR) from the rhizome of Coptis japonica Makino. Arch. Pharm. Res. 29, 757–761.10.1007/BF02968246 [PubMed] [Cross Ref]
  • Min Y. D., Kwon H. C., Yang M. C., Lee K. H., Choi S. U., Lee K. R. (2007). Isolation of limonoids and alkaloids from Phellodendron amurense and their multidrug resistance (MDR) reversal activity. Arch. Pharm. Res. 30, 58–63.10.1007/BF02977779 [PubMed] [Cross Ref]
  • Möller M., Weiss J., Wink M. (2006). Reduction of cytotoxicity of the alkaloid emetine through P-glycoprotein (MDR1/ABCB1) in human Caco-2 cells and leukaemia cell lines. Planta Med. 72, 1121–1126.10.1055/s-2006-941546 [PubMed] [Cross Ref]
  • Molnár J., Engi H., Gyémánt N., Schelz Z., Spengler G., Ocsovski I., Szücs M., Hohmann J., Szabo M., Tanács L. (2008). “Multidrug resistance reversal in cancer cells by selected carotenoids, flavonoids and anthocyanins,” in Bioactive Heterocycles VI, Vol. 15, ed. Motohashi N., editor. (Berlin: Springer; ), 133–159[Topics in Heterocyclic Chemistry].
  • Molnar J., Gyemant N., Mucsi I., Molnar A., Szabo M., Kortvelyesi T., Varga A., Molnar P., Toth G. (2004). Modulation of multidrug resistance and apoptosis of cancer cells by selected carotenoids. In vivo 18, 237–244. [PubMed]
  • Najar I. A., Sachin B. S., Sharma S. C., Satti N. K., Suri K. A., Johri R. K. (2010). Modulation of P-glycoprotein ATPase activity by some phytoconstituents. Phytother. Res. 24, 454–458.10.1002/ptr.2951 [PubMed] [Cross Ref]
  • Nakajima A., Yamamoto Y., Taura K., Hata K., Fukumoto M., Uchinami H., Yonezawa K., Yamaoka Y. (2004). Beneficial effect of cepharanthine on overcoming drug-resistance of hepatocellular carcinoma. Int. J. Oncol. 24, 635–645. [PubMed]
  • Nakaune R. N., Hamamoto H. H., Imada J. I., Akutsu K. A., Hibi T. H. (2002). A novel ABC transporter gene, is involved in multidrug resistance in the phytopathogenic fungus Penicillium digitatum. Mol. Genet. Genomics 267, 179–185.10.1007/s00438-002-0649-6 [PubMed] [Cross Ref]
  • Namanja H. A., Emmert D., Pires M. M., Hrycyna C. A., Chmielewski J. (2009). Inhibition of human P-glycoprotein transport and substrate binding using a galantamine dimer. Biochem. Biophys. Res. Commun. 388, 672–676.10.1016/j.bbrc.2009.08.056 [PMC free article] [PubMed] [Cross Ref]
  • Nielsen D., Skovsgaard T. (1992). P-Glycoprotein as multidrug transporter – a critical-review of current multidrug resistant cell-lines. Biochim. Biophys. Acta 1139, 169–183. [PubMed]
  • Nissler L., Gebhardt R., Berger S. (2004). Flavonoid binding to a multi-drug-resistance transporter protein, an STD-NMR study. Anal. Bioanal. Chem. 379, 1045–1049.10.1007/s00216-004-2701-3 [PubMed] [Cross Ref]
  • Nooter K., Stoter G. (1996). Molecular mechanisms of multidrug resistance in cancer chemotherapy. Pathol. Res. Pract. 192, 768–780.10.1016/S0344-0338(96)80099-9 [PubMed] [Cross Ref]
  • O’Donnell G., Gibbons S. (2007). Antibacterial activity of two canthin-6-one alkaloids from Allium neapolitanum. Phytother. Res. 21, 653–657.10.1002/ptr.2136 [PubMed] [Cross Ref]
  • Ofer M., Langguth P., Spahn-Langguth H. (2006). Bidirectional membrane transport, simulations of transport inhibition in uptake studies explain data obtained with flavonoids. Eur. J. Pharm. Sci. 29, 251–258.10.1016/j.ejps.2006.06.010 [PubMed] [Cross Ref]
  • Ofer M., Wolffram S., Koggel A., Spahn-Langguth H., Langguth P. (2005). Modulation of drug transport by selected flavonoids: involvement of P-gp and OCT? Eur. J. Pharm. Sci. 25, 263–271.10.1016/j.ejps.2005.03.001 [PubMed] [Cross Ref]
  • Ohtani H., Ikegawa T., Honda Y., Kohyama N., Morimoto S., Shoyama Y., Juichi M., Naito M., Tsuruo T., Sawada Y. (2007). Effects of various methoxyflavones on vincristine uptake and multidrug resistance to vincristine in P-gp-overexpressing K562/ADM cells. Pharm. Res. 24, 1936–1943.10.1007/s11095-007-9320-6 [PubMed] [Cross Ref]
  • Okura T., Ibe M., Umegaki K., Shinozuka K., Yamada S. (2010). Effects of dietary ingredients on function and expression of P-glycoprotein in human intestinal epithelial cells. Biol. Pharm. Bull. 33, 255–259.10.1248/bpb.33.255 [PubMed] [Cross Ref]
  • Ordway D., Hohmann J., Viveiros M., Viveiros A., Molnar J., Leandro C., Arroz M. J., Gracio M. A., Amaral L. (2003). Carpobrotus edulis methanol extract inhibits the MDR efflux pumps, enhances killing of phagocytosed S. aureus and promotes immune modulation. Phytother. Res. 17, 512–519.10.1002/ptr.1314 [PubMed] [Cross Ref]
  • Perez-Victoria J. M., Chiquero M. J., Conseil G., Dayan G., Di Pietro A., Barron D., Castanys S., Gamarro F. (1999). Correlation between the affinity of flavonoids binding to the cytosolic site of Leishmania tropica multidrug transporter and their efficiency to revert parasite resistance to daunomycin. Biochemistry 38, 1736–1743.10.1021/bi982455v [PubMed] [Cross Ref]
  • Rethy B., Hohmann J., Minorics R., Varga A., Ocsovszki I., Molnar J., Juhasz K., Falkay G., Zupko I. (2008). Antitumour properties of acridone alkaloids on a murine lymphoma cell line. Anticancer Res. 28, 2737–2743. [PubMed]
  • Robert J., Jarry C. (2003). Multidrug resistance reversal agents. J. Med. Chem. 46, 4805–4817.10.1021/jm030183a [PubMed] [Cross Ref]
  • Rocha Gda G., Simoes M., Lucio K. A., Oliveira R. R., Coelho Kaplan M. A., Gattass C. R. (2007). Natural triterpenoids from Cecropia lyratiloba are cytotoxic to both sensitive and multidrug resistant leukemia cell lines. Bioorg. Med. Chem. 15, 7355–7360.10.1016/j.bmc.2007.07.020 [PubMed] [Cross Ref]
  • Rojas R., Caviedes L., Aponte J. C., Vaisberg A. J., Lewis W. H., Lamas G., Sarasara C., Gilman R. H., Hammond G. B. (2006). Aegicerin, the first oleanane triterpene with wide-ranging antimycobacterial activity, isolated from Clavija procera. J. Nat. Prod. 69, 845–846.10.1021/np050554l [PubMed] [Cross Ref]
  • Scambia G., Ranelletti F. O., Panici P. B., De Vincenzo R., Bonanno G., Ferrandina G., Piantelli M., Bussa S., Rumi C., Cianfriglia M. (1994). Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line, P-glycoprotein as a possible target. Cancer Chemother. Pharmacol. 34, 459–464.10.1007/BF00685655 [PubMed] [Cross Ref]
  • Schinkel A. H., Jonker J. W. (2003). Mammalian drug efflux transporters of the ATP binding cassette (ABC) family, an overview. Adv. Drug Deliv. Rev. 55, 3–29.10.1016/S0169-409X(02)00169-2 [PubMed] [Cross Ref]
  • Severina I. I., Muntyan M. S., Lewis K., Skulachev V. P. (2001). Transfer of cationic antibacterial agents berberine, palmatine, and benzalkonium through bimolecular planar phospholipid film and Staphylococcus aureus membrane. IUBMB Life 52, 321–324.10.1080/152165401317291183 [PubMed] [Cross Ref]
  • Shapiro A. B., Ling V. (1997). Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein. Biochem. Pharmacol. 53, 587–596.10.1016/S0006-2952(96)00826-X [PubMed] [Cross Ref]
  • Sharma S., Kumar M., Nargotra A., Koul S., Khan I. A. (2010). Piperine as an inhibitor of Rv1258c, a putative multidrug efflux pump of Mycobacterium tuberculosis. J. Antimicrob. Chemother. 65, 1694–1701.10.1093/jac/dkq186 [PubMed] [Cross Ref]
  • Smith E. C., Kaatz G. W., Seo S. M., Wareham N., Williamson E. M., Gibbons S. (2007). The phenolic diterpene totarol inhibits multidrug efflux pump activity in Staphylococcus aureus. Antimicrob. Agents Chemother. 51, 4480–4483.10.1128/AAC.00216-07 [PMC free article] [PubMed] [Cross Ref]
  • Solary E., Mannone L., Moreau D., Caillot D., Casasnovas R. O., Guy H., Grandjean M., Wolf J. E., Andre F., Fenaux P. (2000). Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes. Leukemia 14, 2085–2094.10.1038/sj.leu.2401902 [PubMed] [Cross Ref]
  • Steffens J. J., Pell E. J., Tien M. (1996). Mechanisms of fungicide resistance in phytopathogenic fungi. Curr. Opin. Biotechnol. 7, 348–355.10.1016/S0958-1669(96)80043-7 [PubMed] [Cross Ref]
  • Steinbach D., Sell W., Voigt A., Hermann J., Zintl F., Sauerbrey A. (2002). BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia 16, 1443–1447.10.1038/sj.leu.2402541 [PubMed] [Cross Ref]
  • Stermitz F. R., Beeson T. D., Mueller P. J., Hsiang J., Lewis K. (2001). Staphylococcus aureus MDR efflux pump inhibitors from a Berberis and a Mahonia (sensu strictu) species. Biochem. Syst. Ecol. 29, 793–798.10.1016/S0305-1978(01)00025-4 [PubMed] [Cross Ref]
  • Stermitz F. R., Lorenz P., Tawara J. N., Zenewicz L. A., Lewis K. (2000a). Synergy in a medicinal plant, antimicrobial action of berberine potentiated by 5′-methoxyhydnocarpin, a multidrug pump inhibitor. Proc. Natl. Acad. Sci. U.S.A. 97, 1433–1437.10.1073/pnas.030540597 [PMC free article] [PubMed] [Cross Ref]
  • Stermitz F. R., Tawara-Matsuda J., Lorenz P., Mueller P., Zenewicz L., Lewis K. (2000b), 5′-Methoxyhydnocarpin-D and pheophorbide A, Berberis species components that potentiate berberine growth inhibition of resistant Staphylococcus aureus. J. Nat. Prod. 63, 1146–1149. [PubMed]
  • Stermitz F. R., Scriven L. N., Tegos G., Lewis K. (2002). Two flavonols from Artemisia annua which potentiate the activity of berberine and norfloxacin against a resistant strain of Staphylococcus aureus. Planta Med. 68, 1140–1141.10.1055/s-2002-36347 [PubMed] [Cross Ref]
  • Suttana W., Mankhetkorn S., Poompimon W., Palagani A., Zhokhov S., Gerlo S., Haegeman G., Berghe W. V. (2010). Differential chemosensitization of P-glycoprotein overexpressing K562/Adr cells by withaferin A and Siamois polyphenols. Mol. Cancer 9, 99.10.1186/1476-4598-9-99 [PMC free article] [PubMed] [Cross Ref]
  • Suzuki H., Tanabe H., Mizukami H., Inoue M. (2010). Selective regulation of multidrug resistance protein in vascular smooth muscle cells by the isoquinoline alkaloid coptisine. Biol. Pharm. Bull. 33, 677–682.10.1248/bpb.33.677 [PubMed] [Cross Ref]
  • Tang S., Bremner P., Kortenkamp A., Schlage C., Gray A. I., Gibbons S., Heinrich M. (2003). Biflavonoids with cytotoxic and antibacterial activity from Ochna macrocalyx. Planta Med. 69, 247–253.10.1055/s-2003-37718 [PubMed] [Cross Ref]
  • Taur J. S., Rodriguez-Proteau R. (2008). Effects of dietary flavonoids on the transport of cimetidine via P-glycoprotein and cationic transporters in Caco-2 and LLC-PK1 cell models. Xenobiotica 38, 1536–1550.10.1080/00498250802499467 [PubMed] [Cross Ref]
  • Tian H., Pan O. C. (1997). Modulation of multidrug resistance by three bisbenzyl-isoquinolines in comparison with verapamil. Zhongguo Yao Li Xue Bao 18, 455–458. [PubMed]
  • Tournier N., Chevillard L., Megarbane B., Pirnay S., Scherrmann J. M., Decleves X. (2010). Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int. J. Neuropsychopharmacol. 13, 905–915.10.1017/S1461145709990848 [PubMed] [Cross Ref]
  • Trompier D., Baubichon-Cortay H., Chang X. B., Maitrejean M., Barron D., Riordon J. R., Di Pietro A. (2003). Multiple flavonoid-binding sites within multidrug resistance protein MRP1. Cell. Mol. Life Sci. 60, 2164–2177.10.1007/s00018-003-3177-6 [PubMed] [Cross Ref]
  • Twentyman P. R., Bleehen N. M. (1991). Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin. Eur. J. Cancer 27, 1639–1642.10.1016/0277-5379(91)90435-G [PubMed] [Cross Ref]
  • van der Kolk D. M., Vellenga E., Müller M., De Vries E. G. E. (1999). Multidrug resistance protein MRP1, glutathione, and related enzymes – their importance in acute myeloid leukemia. Adv. Exp. Med. Biol. 457, 187–198.10.1007/978-1-4615-4811-9_20 [PubMed] [Cross Ref]
  • van Gorkom B. A., Timmer-Bosscha H., de Jong S., van der Kolk D. M., Kleibeuker J. H., de Vries E. G. (2002). Cytotoxicity of rhein, the active metabolite of sennoside laxatives, is reduced by multidrug resistance-associated protein 1. Br. J. Cancer 86, 1494–1500.10.1038/sj.bjc.6600255 [PMC free article] [PubMed] [Cross Ref]
  • Versantvoort C. H., Broxterman H. J., Lankelma J., Feller N., Pinedo H. M. (1994). Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells. Biochem. Pharmacol. 48, 1129–1136.10.1016/0006-2952(94)90149-X [PubMed] [Cross Ref]
  • Versantvoort C. H., Rhodes T., Twentyman P. R. (1996). Acceleration of MRP-associated efflux of rhodamine 123 by genistein and related compounds. Br. J. Cancer 74, 1949–1954.10.1038/bjc.1996.658 [PMC free article] [PubMed] [Cross Ref]
  • Wang F. P., Wang L., Yang J. S., Nomura M., Miyamoto K. (2005). Reversal of P-glycoprotein-dependent resistance to vinblastine by newly synthesized bisbenzylisoquinoline alkaloids in mouse leukemia P388 cells. Biol. Pharm. Bull. 28, 1979–1982.10.1248/bpb.28.1966 [PubMed] [Cross Ref]
  • Wang L., Bai L., Nagasawa T., Hasegawa T., Yang X., Sakai J., Bai Y., Kataoka T., Oka S., Hirose K. (2008). Bioactive triterpene saponins from the roots of Phytolacca americana. J. Nat. Prod. 71, 35–40.10.1021/np7007522 [PubMed] [Cross Ref]
  • Watanabe T., Tsuge H., Oh-Hara T., Naito M., Tsuruo T. (1995). Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol 34, 235–241.10.3109/02841869509093961 [PubMed] [Cross Ref]
  • Weerasinghe P., Hallock S., Tang S. C., Trump B., Liepins A. (2006). Sanguinarine overcomes P-glycoprotein-mediated multidrug-resistance via induction of apoptosis and oncosis in CEM-VLB 1000 cells. Exp. Toxicol. Pathol. 58, 21–30.10.1016/j.etp.2006.01.008 [PubMed] [Cross Ref]
  • Wei D., Mei Y., Liu J. (2003). Quantification of doxorubicin and validation of reversal effect of tea polyphenols on multidrug resistance in human carcinoma cells. Biotechnol. Lett. 25, 291–294.10.1023/A:1024034508136 [PubMed] [Cross Ref]
  • Wesolowska O., Hendrich A. B., Laniapietrzak B., Wisniewski J., Molnar J., Ocsovszki I., Michalak K. (2009). Perturbation of the lipid phase of a membrane is not involved in the modulation of MRP1 transport activity by flavonoids. Cell. Mol. Biol. Lett. 14, 199–221.10.2478/s11658-008-0044-3 [PubMed] [Cross Ref]
  • Wesolowska O., Wisniewski J., Duarte N., Ferreira M. J., Michalak K. (2007). Inhibition of MRP1 transport activity by phenolic and terpenic compounds isolated from Euphorbia species. Anticancer Res. 27, 4127–4133. [PubMed]
  • Wijnholds J., deLange E. C., Scheffer G. L., van den Berg D. J., Mol C. A., van der Valk M., Schinkel A. H., Scheper R. J., Breimer D. D., Borst P. (2000). Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J. Clin. Invest. 105, 279–285.10.1172/JCI8267 [PMC free article] [PubMed] [Cross Ref]
  • Wink M. (1988). Plant breeding: importance of plant secondary metabolites for protection against pathogens and herbivores. Theor. Appl. Genet. 75, 225–233.10.1007/BF00303957 [Cross Ref]
  • Wink M. (1993). Allelochemical properties and the raison d’être of alkaloids. Alkaloids Chem. Biol. 43, 1–118.
  • Wink M. (2000). Interference of alkaloids with neuroreceptors and ion channels. Nat. Prod. Res. 21, 3–129.
  • Wink M. (2003). Evolution of secondary metabolites from an ecological and molecular phylogenetic perspective. Phytochemistry 64, 3–19.10.1016/S0031-9422(03)00300-5 [PubMed] [Cross Ref]
  • Wink M. (2007). Molecular modes of action of cytotoxic alkaloids- from DNA intercalation, spindle poisoning, topoisomerase inhibition to apoptosis and multiple drug resistance. Alkaloids Chem. Biol. 64, 1–48.10.1016/S1099-4831(07)64001-2 [PubMed] [Cross Ref]
  • Wink M. (2008a). Plant secondary metabolism: diversity, function and its evolution. Nat. Prod. Commun. 3, 1205–1216.
  • Wink M. (2008b). Evolutionary advantage and molecular modes of action of multi-component mixtures used in phytomedicine. Curr. Drug Metab. 9, 996–1009.10.2174/138920008786927794 [PubMed] [Cross Ref]
  • Wink M. (2010a). Functions and Biotechnology of Plant Secondary Metabolites – Annual Plant Reviews, Vol. 39 Chichester: Wiley-Blackwell.
  • Wink M. (2010b). Biochemistry of Plant Secondary Metabolism – Annual Plant Reviews, Vol. 40 Chichester: Wiley-Blackwell.
  • Wink M., Schimmer O. (2010). “Molecular modes of action of defensive secondary metabolites,” in Functions and Biotechnology of Plant Secondary Metabolites, Vol. 39, ed. Wink M., editor. (Chichester: Wiley-Blackwell; ), 21–161.
  • Xu W. L., Shen H. L., Ao Z. F., Chen B. A., Xia W., Gao F., Zhang Y. N. (2006). Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia. Leuk. Res. 30, 407–413.10.1016/j.leukres.2005.05.023 [PubMed] [Cross Ref]
  • Yasuda K., Lan L. B., Sanglard D., Furuya K., Schuetz J. D., Schuetz E. G. (2002). Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J. Pharmacol. Exp. Ther. 303, 323–332.10.1124/jpet.102.037549 [PubMed] [Cross Ref]
  • Ye J., Zheng Y., Liu D. (2009). Reversal effect and its mechanism of ampelopsin on multidrug resistance in K562/ADR cells. Zhongguo Zhong Yao Za Zhi 34, 761–765. [PubMed]
  • Yoo H. H., Lee M., Chung H. J., Lee S. K., Kim D.-H. (2007). Effects of diosmin, a flavonoid glycoside in citrus fruits, on P-glycoprotein-mediated drug efflux in human intestinal Caco-2 cells. J. Agric. Food Chem. 55, 7620–7625.10.1021/jf062603l [PubMed] [Cross Ref]
  • Yoshida N., Takagi A., Kitazawa H., Kawakami J., Adachi I. (2005). Inhibition of P-glycoprotein-mediated transport by extracts of and monoterpenoids contained in Zanthoxyli fructus. Toxicol. Appl. Pharmacol. 209, 167–173.10.1016/j.taap.2005.04.001 [PubMed] [Cross Ref]
  • You G., Morris M. E. (2007). Drug Transporters- Molecular Characterization and Role in Drug Disposition. Hoboken, NJ: Wiley-Interscience.
  • You M., Ma X., Mukherjee R., Farnsworth N. R., Cordell G. A., Kinghorn A. D., Pezzuto J. M. (1994). Indole alkaloids from Peschiera laeta that enhance vinblastine-mediated cytotoxicity with multidrug-resistant cells. J. Nat. Prod. 57, 1517–1522.10.1021/np50113a007 [PubMed] [Cross Ref]
  • You M., Wickramaratne D. B., Silva G. L., Chai H., Chagwedera T. E., Farnsworth N. R., Cordell G. A., Kinghorn A. D., Pezzuto J. M. (1995). (-)-Roemerine, an aporphine alkaloid from Annona senegalensis that reverses the multidrug-resistance phenotype with cultured cells. J. Nat. Prod. 58, 598–604.10.1021/np50118a021 [PubMed] [Cross Ref]
  • Zamora J. M., Pearce H. L., Beck W. T. (1988). Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol. Pharmacol. 33, 454–462. [PubMed]
  • Zhang S., Morris M. E. (2003). Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J. Pharmacol. Exp. Ther. 304, 1258–1267.10.1124/jpet.102.044412 [PubMed] [Cross Ref]
  • Zhang S., Yang X., Morris M. E. (2004). Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol. Pharmacol. 65, 1208–1216.10.1124/mol.65.5.1208 [PubMed] [Cross Ref]
  • Zhao M., Bai L., Wang L., Toki A., Hasegawa T., Kikuchi M., Abe M., Sakai J., Hasegawa R., Bai Y. (2007). Bioactive cardenolides from the stems and twigs of Nerium oleander. J. Nat. Prod. 70, 1098–1103.10.1021/np0703850 [PubMed] [Cross Ref]
  • Zhou D. C., Zittoun R., Marie J. P. (1995). Homoharringtonine, an effective new natural product in cancer chemotherapy. Bull. Cancer 82, 987–995. [PubMed]
  • Zhou S., Lim L. Y., Chowbay B. (2004). Herbal modulation of P-glycoprotein. Drug Metab. Rev. 36, 57–104.10.1081/DMR-120028427 [PubMed] [Cross Ref]
  • Zhu A., Wang X., Guo Z. (2001). Study of tea polyphenol as a reversal agent for carcinoma cell lines’ multidrug resistance (study of TP as a MDR reversal agent). Nucl. Med. Biol. 28, 735–740.10.1016/S0969-8051(00)90202-6 [PubMed] [Cross Ref]
  • Zhu X., Sui M., Fan W. (2005). In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel. Anticancer Res. 25, 1953–1962. [PubMed]
  • Zupko I., Rethy B., Hohmann J., Molnar J., Ocsovszki I., Falkay G. (2009). Antitumor activity of alkaloids derived from Amaryllidaceae species. In vivo 23, 41–48. [PubMed]

Articles from Frontiers in Microbiology are provided here courtesy of Frontiers Media SA

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...